MOREHOUSE SCHOOL OF MEDICINE ATLANTA GA ATLANTA United States
The primary goal of this project is to elucidate the mechanism of action of thymoquinone TQ against docetaxel DTX-resistant, metastatic castration-resistant prostate cancer mCRPC. We formulated a novel TQ nanoparticles NPs capable of rapid clinical translation we utilized a highly innovative-patented NP platform, the planetary ball-milling PBM platform. In this study, we investigate whether thymoquinone directly inhibits ABCB1 transporter activity in mCRPC cells. We found that TQ can now bind and inhibit the transporter activity of ABCB1, thereby enhancing the cytotoxicity of DTX in mCRPC cells. We have also identified thymoquinone inhibits the transcription of ABCB1 through a ZEB1-dependent mechanism.